FOR UK HEALTHCARE PROFESSIONALS ONLY
For UK Healthcare Professionals Only

Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

DAYS
hours
minutes

ADvance 2021

ADvance NORTH: 22nd April 2021, 18:30–20:00

ADvance SOUTH: 29th April 2021, 18:30–20:00

REGISTER HERE

DUPIXENT was studied in children aged 6–11 years old with severe AD who were inadequately controlled by topical treatments1

Find out more
 

Discover the emerging science in AD from experts in the field.

Find out more

The first targeted immunomodulator for patients aged 12 years and older with moderate-to-severe AD and for children aged 6–11 years with severe AD, who are candidates for systematic therapy1,2

EXPLORE MODE OF ACTION

Resources

Find out what additional resources are available to download to provide you with further information about DUPIXENT and support you in treating your patients with moderate-to-severe AD (aged 12 years and older) and severe AD (ages 6–11).

Find out more

DUPIXENT (dupilumab) is indicated for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged 12 years or older and for severe AD in children aged 6–11 years, who are candidates for systemic therapy1

Type 2 inflammation contributes to clinical disease features of AD2-4

Find out more

Real-world evidence (RWE) studied in a UK tertiary care setting5

Find out more

>163,000

patients

aged 12 years or older with moderate-to-severe AD and children aged 6–11 years old with severe AD have been prescribed DUPIXENT in the U.S.A and Europe as of November 20206

251 adolescent patients with moderate-to-severe AD that were inadequately controlled with topical treatments, participated in a study (AD-1526) to investigate the efficacy of DUPIXENT as a monotherapy for up to 16 weeks1

Find out more

LATEST NEWS & EVENTS

 

Type 2 Inflammation

IL-4 and IL-13 are key drivers of Type 2 inflammation2

Read more

Efficacy in children

Explore the efficacy data in children aged 6–11 years old with severe AD

Read more

Safety profile in children

Learn more about the safety profile of DUPIXENT in children aged 6–11 years old with severe AD

Read more

RWE efficacy

Efficacy and safety were reviewed in RWE studies5

Read more

Targeted therapy towards IL-4 and IL-13, key drivers of persistent underlying Type 2 inflammation1,2

Safety has been investigated in patients for up to 52 weeks in adolescents and children and 3 years in adults1,10–12

Improvements in lesion extent and severity compared to placebo at 16 weeks in all populations and sustained in adults at 52 weeks1,7–9

DUPIXENT can be self-administered by subcutaneous injection using the pre-filled syringe or pre-filled pen. The pre-filled syringe is the only presentation appropriate for use in children 6–11 years old*1

*The DUPIXENT pre-filled pen is not intended for use in children below 12 years of age. For children 6 to 11 years of age with severe AD, the DUPIXENT pre-filled syringe is the presentation appropriate for administration to this population.1


AD, atopic dermatitis; IL, interleukin; RWE, real-world evidence.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: April 2021.
  2. Gandhi NA, et al. Nature Rev Drug Disc. 2016; 15: 35–50.
  3. Gittler JK, et al. J Allergy Clin Immunol. 2012;130(6):1344–1354.
  4. Biedermann T, et al. Front Immunol. 2015;6:353.
  5. Kreeshan, F.C, et al. Dermatol Ther. 2020. doi.org/10.1007/s13555-020-00469-6.
  6. Sanofi Data on File. MAT-IE-2000837 (v2.0).
  7. Simpson EL, et al. JAMA Dermatol. 2020;156(1):44–56.
  8. Blauvelt A, et al. Lancet. 2017;389(10086):2287–2303.
  9. Paller, AS et al. J Am Acad Dermatol. 2020;83(5): 1282–1293. doi:10.1016/j.jaad.2020.06.054.
  10. Thaçi D, et al. Favorable Safety and Sustained Efficacy With Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis up to 3 Years (LIBERTY AD OLE) presented at the 20th Annual Las Vegas Dermatology Seminar, Nevada, USA, November 7–9 2019.
  11. Cork MJ, et al. Br J Dermatol. 2020;182(1):85–96.
  12. Cork MJ, et al. Br J Dermatol. 2020. doi: 10.1111/bjd.19460.